Key messages from EBC MAIN at three years

1840

EBC MAIN investigator David Hildick-Smith (Brighton, UK) delivers key messages from the trial’s three-year results, presented for the first time at EuroPCR 2023 (16–19 May, Paris, France).

The randomised trial compares a provisional versus a systematic dual stent strategy for true bifurcation left main coronary artery disease at over 30 centres across Europe.

Among the important takeaway messages from the trial, Hildick-Smith tells Cardiovascular News, is that interventionalists do not need to decide on the number of stents they intend to use prior to the procedure.


LEAVE A REPLY

Please enter your comment!
Please enter your name here